tom...I meant to make this the first non-principal to post on your new board, but when I tried to submit iHub had a problem with your board. To bad really cause I think it's a doozy. I ordered the complete TWST CEO Interview with Tony Frudakis...all nine pages. Fascinating stuff in there.
It is copyrighted material so I can't reproduce it verbatim here on the board. It is available through yahoo business for $50.00 for anyone wishing to get the short term and long term outlook from DNAPrint's perspective.
In it Dr. Frudakis discusses in greater detail what he means by DNAPrint becoming a pharmaceutical company (they are working very hard at acquiring their own drug pipeline right now); a general time frame for the addition of up to 100 employees; the need for a larger building and the fact that they would build new, not build out; the need for an additional high throughput genotyping system devoted to clinical genotyping (even though the one they have does 160,000 genotypes per day); they will have a clinical genotyping operation up and running by the end of the year; near-term capital financing by their investment banking group; company Management - including a new Director of Marketing and new Medical Officer; the need to graduate from the OTCBB in a way that doesn't alienate existing investors coupled with the graduation to a pharma company (It will not be a bunch of small changes, but rather a couple of very dramatic changes that lead to DNAPrint becoming a NASDAQ stock).
DNAP's success is derived from reading MORE than just the xenobiotic metablolism genes (as everyone else does) which tells only half the story concerning drug response. In order to understand upwards of 90-95% of the causes of drug response, one needs to be able to look at genomes. This is what we do and ONLY we can do that.
Again, I don't want to quote directly from the document, but the bottom line is that Tony says that long term their business is about developing the most powerful drugs that have ever been developed. They're in the process of completing some steps that are intermediate to that goal. That is referred to as Plan B, Plan A involves our work with existing drugs (such as Lipitor and Taxol) and will generate the near term revenues they need for growth.
This is an excellent interview that is full of good strategic information. Expect about $150K in revenue this quarter (which sounds light to me). The report doesn't indicate how much deferred income. Says we are reaching the point where we are probably going to make $1M/year from Ancestry alone, not counting forensics profiling revenue which is just getting started.
Lastly, no mention of what's going on in Malaysia whatsoever. But I'm guessing this will be an interesting 10Q.
Later,
W2P
Market Data 
Markets 
AI
